Evidence map›Paper›PMID 38781221›Full record

SynthesisPloS one2024

Anthracycline-induced arrhythmias in breast cancer therapy: A meta-analysis of single-arm trials.

Tao Ran, Jinyao Chen, Qiurui She, Yi Mu, Min Zhang, Min Mao, Zhong Zuo, Juan Li

Abstract readMeta-Analysis
In one paragraph

Synthesis in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tao RanDepartment of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Jinyao ChenSchool of the First Clinical Medical College, Chongqing Medical University, Chongqing, China.
Qiurui SheSchool of the First Clinical Medical College, Chongqing Medical University, Chongqing, China.
Yi MuSchool of the First Clinical Medical College, Chongqing Medical University, Chongqing, China.
Min ZhangSchool of Public Health and Management, Chongqing Medical University, Chongqing, China.
Min MaoDepartment of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Zhong ZuoDepartment of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Juan LiDepartment of Academic Affairs, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.ORCID 0000-0002-8892-1642

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAs of 2020, breast cancer has emerged as the predominant cause of cancer incidence globally. Anthracycline-based chemotherapy serves as a crucial element in the treatment regimen for breast cancer. However, these anthracycline-based drugs are associated with cardiac toxicity. This study represents the first clinical quantitative analysis aimed at accurately determining the incidences of arrhythmia and abnormal electrocardiogram (ECG) changes, thereby providing valuable data to bolster clinical drug usage and monitoring.

methodsA systematic search was conducted across multiple databases including CNKI, VIP, Wanfang, PubMed, Embase, Web of Science, and the Cochrane Library. The incidence of combined arrhythmias in breast cancer patients and the associated heterogeneity were calculated using either a random effect model or a fixed effect model. Statistical analysis was performed using STATA16.

resultsThe study encompassed a total of 37 articles, which included 5705 breast cancer patients undergoing anthracycline treatment. Among these patients, 2257 developed arrhythmias. The meta-analysis revealed that the incidence of anthracycline-associated arrhythmias and abnormal ECG changes in breast cancer patients was 0.41 (0.37, 0.44). Subgroup analysis indicated that the incidence of ST-T segment change was 0.19 (0.15, 0.23), the incidence of conduction block was 0.04 (0.02, 0.05), the incidence of premature beats was 0.09 (0.07, 0.11), and the incidence of atrial fibrillation was 0.04 (0.00, 0.12). Additional results are presented in Table 3.

conclusionThis pioneering study accurately assesses the incidence of arrhythmias in breast cancer patients treated with anthracyclines. The findings provide clinicians with valuable insights into understanding and managing the cardiac toxicity associated with such treatment. Moreover, this study lays the foundation for future research exploring the mechanisms underlying these arrhythmias and potential preventative strategies.

Indexed as

AnthracyclinesArrhythmias, CardiacBreast NeoplasmsClinical Trials as TopicElectrocardiographyFemaleHumansIncidenceAnthracyclines

Identifiers

PMID38781221
PMCPMC11115293

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.